FDA
-
-
-
-
-
-
-
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) PT Lowered to $45 at Wells Fargo
-
-
-
-
-
-
-
Ultragenyx reports positive 96-week data for GSDIa gene therapy DTX401
-
-
-
-
-
-
-
Health Canada approves Evkeeza for infants as young as 6 months with HoFH
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with San
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

